Proactive Investors - Run By Investors For Investors

Sativa Investments' investee firm Rapid Dose Therapeutics begins trading on CSE

Rapid Dose Therapeutics has made an initial paper profit of C$140,000 for Savita Investments, an increase of 70%, after just seven months
cannanis
Rapid Dose Therapeutics has developed a fast-dissolving medicinal cannabis strip

Bio-technology firm Rapid Dose Therapeutics Inc (CSE:DOSE), an investee business of medicinal cannabis investor Sativa Investments PLC (LON:SATI), has been admitted to trading on the Canadian Stock Exchange.

Sativa Investments, which is the UK’s first medicinal cannabis investment firm, subscribed for 400,000 shares at C$50 each in Rapid Dose Therapeutics for C$200,000 in cash ahead of the listing on Monday.

At the close on Monday, shares were trading hands at C$0.85 each.

WATCH: Sativa Investments 'at the forefront' of developing UK medical cannabis market

Rapid Dose Therapeutics has developed a fast-dissolving medicinal cannabis strip, called Quickstrip, that is placed on or under the tongue, or inside the cheek. The company also sells pharmaceuticals, emulsified oils and over-the-counter medicines across North America.

The firm has made an initial paper profit of C$140,000 for Savita Investments, an increase of 70%, after just seven months.

"RDT's technology has very positive implications for both Sativa's medicinal cannabis business and its CBD (cannabidiol) focused 100% subsidiary George Botanicals Limited, and we look forward to continued collaboration with RDT alongside our investment." 

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full SATI profile View Profile

Sativa Group PLC Timeline

Related Articles

harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
An instrument made by Pressure BioSciences
June 26 2019
The company’s high-pressure technologies can help drug makers produce protein-based therapeutics, a market expected to touch $240 billion by 2023
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use